Generics
Mylan, Synthon, receive favourable UK High Court decision regarding Teva Phamaceutical's Copaxone dispute
30 October 2017 -

United States-based Mylan and Netherlands-based Synthon have received a favourable decision in the UK High Court of Justice in their dispute regarding the patent of Israel-based Teva Phamaceutical Industries' multiple sclerosis drug, Copaxone, which was ruled to be invalid because of obviousness, it was reported on Friday.

Synthon is the partner of the United States-based Mylan for the development and supply of its Glatiramer Acetate Injection 40mg/mL product across Europe.

The three-times-a-week injection is the substitutable generic version of Teva's Copaxone 40mg/mL, which had received approval from the US Food and Drug Administration (FDA) earlier this month. The company further stated that the positive judgment gained in the United Kingdom for the Copaxone generic will help further clear the way for its launches of Glatiramer Acetate Injection 40mg/mL in the future in select European markets.

Teva stated that it is disappointed and disagrees with the ruling over its patent, and intends to appeal against it in the UK Court of Appeal, as reported in The Times of Israel.

Login
Username:

Password: